AbbVie paid $10.9B for zumilokibart's ultra-long dosing edge in AD; Phase 3 execution now determines whether that premium was justified

Apogee Therapeutics is a clinical-stage company acquired by AbbVie developing zumilokibart, a targeted biologic not yet approved, to treat atopic dermatitis, asthma, and eosinophilic esophagitis.

AbbVie acquired Apogee for $135.11 per share in September 2026, betting that zumilokibart's 3-to-6-month dosing interval can carve durable share from entrenched competitors in atopic dermatitis, asthma, and eosinophilic esophagitis. The APEX Part B induction data showed 65.9% EASI-75 on mid-dose versus 23.4% placebo, clearing the bar for Phase 3 initiation, but registrational success hinges on replicating that efficacy at scale in a crowded biologics field. The absorption into AbbVie eliminates financing risk while shifting the question entirely to whether Phase 3 data confirm the dosing differentiation that justified the acquisition price.